Inhibition of cyclooxygenase-2 expression and prostaglandin E2 production in chondrocytes by avocado soybean unsaponifiables and epigallocatechin gallate

Osteoarthritis Cartilage. 2010 Feb;18(2):220-7. doi: 10.1016/j.joca.2009.08.015. Epub 2009 Sep 6.

Abstract

Objective: To evaluate the anti-inflammatory effect of the combination of avocado soybean unsaponifiables (ASU) and epigallocatechin gallate (EGCG) on cyclooxygenase-2 (COX-2) expression and prostaglandin E(2) (PGE(2)) production in cytokine-activated equine chondrocytes.

Methods: Production of type II collagen and aggrecan was verified by immunohistochemistry and Western blot. Chondrocytes were incubated with: (1) control media alone, (2) ASU (4 microg/ml; 8.3 microg/ml), (3) EGCG (4, 40, 400 ng/ml), or (4) the combination of ASU and EGCG for 24h. Cells were next incubated with control medium alone or with IL-1beta (10 ng/ml) and TNF-alpha (1 ng/ml). COX-2 gene expression by real-time PCR analysis and NF-kappaB nuclear translocation by immunohistochemistry were performed after 1h of incubation. PGE(2) production was determined by immunoassay after 24h of incubation.

Results: Equine chondrocytes responded to cytokine activation by up-regulated gene expression of COX-2 and increased PGE(2) production. Activation was associated with NF-kappaB translocation. Individually, ASU and EGCG marginally inhibited COX-2 expression and PGE(2) production in activated chondrocytes. In contrast, the combination of ASU and EGCG reduced COX-2 expression close to non-activated control levels and significantly inhibited PGE(2) production. These reductions were statistically greater than those of ASU or EGCG alone. The inhibition of COX-2 expression and PGE(2) production was associated with inhibition of NF-kappaB translocation.

Conclusion: The present study demonstrates that the anti-inflammatory activity of ASU and EGCG is potentiated when used in combination. This combination may offer an attractive supplement or alternative to non-steroidal anti-inflammatory drugs (NSAIDs) in the management of osteoarthritis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aggrecans / metabolism
  • Animals
  • Antioxidants
  • Cartilage, Articular / enzymology
  • Cartilage, Articular / metabolism
  • Catechin / analogs & derivatives*
  • Catechin / pharmacology
  • Chondrocytes / enzymology
  • Chondrocytes / metabolism*
  • Collagen Type II / metabolism
  • Cyclooxygenase 2 / genetics
  • Cyclooxygenase 2 / metabolism*
  • Dinoprostone / genetics
  • Dinoprostone / metabolism*
  • Disease Models, Animal
  • Gene Expression
  • Glycine max*
  • Horses
  • Interleukin-1beta / pharmacology
  • NF-kappa B / metabolism
  • Persea*
  • Phenotype
  • Plant Extracts / pharmacology*
  • Polymerase Chain Reaction
  • RNA / analysis
  • Tumor Necrosis Factor-alpha / pharmacology

Substances

  • Aggrecans
  • Antioxidants
  • Collagen Type II
  • Interleukin-1beta
  • NF-kappa B
  • Plant Extracts
  • Tumor Necrosis Factor-alpha
  • RNA
  • Catechin
  • epigallocatechin gallate
  • Cyclooxygenase 2
  • Dinoprostone